What is Phenylbutazone used for?

Phenylbutazone, often marketed under trade names such as Butazolidin, is a nonsteroidal anti-inflammatory drug (NSAID) primarily utilized for its potent analgesic and anti-inflammatory properties. Initially developed in the 1940s, Phenylbutazone has since found applications in both human and veterinary medicine. However, its use in humans has become quite limited due to significant safety concerns. Phenylbutazone targets cyclooxygenase (COX) enzymes, specifically COX-1 and COX-2, which are integral to the inflammatory response. Research institutions globally have investigated its broad spectrum of applications, but its primary indications have been for the treatment of chronic inflammatory conditions such as rheumatoid arthritis, ankylosing spondylitis, and gouty arthritis. Despite its efficacy, research progress has highlighted serious side effects that have curtailed its use in modern medical practice.

Phenylbutazone works by inhibiting the activity of cyclooxygenase (COX) enzymes, which play a crucial role in the formation of prostaglandins. Prostaglandins are lipid compounds that mediate various physiological responses, including inflammation, pain, and fever. By blocking COX-1 and COX-2 enzymes, Phenylbutazone effectively reduces the synthesis of these inflammatory mediators, thereby alleviating pain and inflammation. Its anti-inflammatory properties are particularly beneficial in conditions characterized by severe inflammation and pain. However, the inhibition of COX-1 can also lead to unwanted gastrointestinal and renal side effects, as this enzyme also protects the stomach lining and maintains kidney function. The drug's ability to diminish both COX-1 and COX-2 activity accounts for its potent anti-inflammatory effects but also poses significant risks.

 

Researching Phenylbutazone beyond the basics?

Synapse Hiro LS Researcher, the Synapse AI Insight Engine, is built to accelerate biopharma decisions. Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence. Explore Phenylbutazone with Hiro LS Researcher →

Phenylbutazone is generally administered orally, though it can also be given intravenously or intramuscularly in specific circumstances. The oral route is the most common form of administration, typically in tablet or paste form. The onset of action usually occurs within one to two hours after administration, making it relatively fast-acting. In veterinary medicine, particularly for horses, Phenylbutazone is often given in paste form to manage conditions such as lameness and musculoskeletal pain. The dosage and frequency of administration depend on the severity of the condition and the specific needs of the patient or animal. It is crucial to adhere to prescribed dosages to mitigate the risk of adverse effects and toxicity. Long-term use generally necessitates regular monitoring, including blood tests, to ensure that the drug is not causing harm to vital organs.

Despite its effectiveness, Phenylbutazone is associated with a range of side effects that limit its use, particularly in humans. One of the most concerning adverse effects is its potential to cause gastrointestinal ulceration and bleeding, a consequence of COX-1 inhibition. Other common side effects include nausea, vomiting, and abdominal pain. In severe cases, Phenylbutazone can lead to kidney damage and liver toxicity, necessitating regular monitoring of renal and liver function during prolonged use. Hematological side effects, such as aplastic anemia and agranulocytosis, are rare but extremely serious and have led to caution in its use. Contraindications for Phenylbutazone include pre-existing gastrointestinal ulcers, renal impairment, liver disease, and hematological disorders. Pregnant and breastfeeding women are also advised against using this drug due to potential risks to the fetus and infant. Given these significant risks, Phenylbutazone is no longer a first-line treatment for inflammatory conditions in humans and is used primarily in veterinary settings.

Phenylbutazone is metabolized in the liver and excreted through the kidneys, so it has the potential to interact with various other medications. Drugs that also undergo hepatic metabolism, such as barbiturates and rifampin, can accelerate the breakdown of Phenylbutazone, reducing its effectiveness. Concurrent use with other NSAIDs or corticosteroids can amplify the risk of gastrointestinal ulceration and bleeding. Anti-coagulants like warfarin may see their effects potentiated by Phenylbutazone, increasing the risk of bleeding complications. Additionally, phenylbutazone can displace other drugs from plasma protein binding sites, enhancing their effects and toxicity. For instance, it can increase the levels of hypoglycemic agents, leading to dangerous drops in blood sugar levels. Due to these potential interactions, it is imperative to review all medications a patient is taking before initiating Phenylbutazone therapy. Adjustments in dosages or alternative treatments may be necessary to ensure safety and efficacy.

Continue your Phenylbutazone research with Synapse Hiro LS Researcher

This article provides an overview. For a broader research view, use Synapse Hiro LS Researcher—the Synapse AI Insight Engine—to search across drugs, targets, indications, clinical trials, literature, organizations, news, deals, and competitor signals. Ask any biopharma research question in natural language.

Questions to explore:

• What approved and investigational uses have been reported for Phenylbutazone?
• What is the mechanism of action of Phenylbutazone, and which targets or pathways are involved?
• Which clinical trials are evaluating Phenylbutazone, and what outcomes have been reported?
• What patents, publications, and regulatory sources provide the latest evidence on Phenylbutazone?

Ask Synapse Hiro LS Researcher →

AI may make mistakes. Check important info.